Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA

Journal of Human Virology

Volumn 4, Issue 1, 2001, Pages 39-43

  Moss, R B ^a   Diveley, J ^a   Jensen, F C ^a   Gouveia, E ^a   Carlo, D J ^a  

^a Orchestra Therapeutics Inc   (United States)

Author keywords

HIV specific immune responses; Preventive vaccine; Simultaneous vaccination

Indexed keywords

BETA CHEMOKINE; CYTOSINE DERIVATIVE; FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GUANINE NUCLEOTIDE; IMMUNOGLOBULIN G; PHOSPHOROTHIOIC ACID DERIVATIVE; RANTES; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RAT; VACCINATION;

AIDS VACCINES; ANIMALS; CPG ISLANDS; DNA, VIRAL; FREUND'S ADJUVANT; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INTERFERON TYPE II; LIPIDS; OLIGODEOXYRIBONUCLEOTIDES; RANTES; RATS; RATS, INBRED LEW; VACCINATION; VACCINES, DNA;

EID: 0035147582     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
2. CpG DNA. A novel immune enhancer for systemic and mucosal immunization with influenza virus
3. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
4. Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity
5. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides
6. Protective immunity against HIV infection: Has nature done the experiment for us?
7. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response
8. Sequence Note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant
9. Process development for the manufacture of inactivated HIV-1
10. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen
11. + T cells
12. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection
13. News focus: Can immune systems be trained to fight HIV?
14. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status
15. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication
16. Betachemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques